Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients


Autoria(s): BALTIERI, Danilo Antonio; DARO, Fabio Ruiz; RIBEIRO, Philip Leite; ANDRADE, Arthur Guerra de
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2009

Resumo

Background: A high smoking prevalence has been registered among alcoholics. It has been pointed out that alcoholic smokers may have a more severe course and greater severity of alcoholism. This study aims at comparing smoking and non-smoking alcoholics in terms of treatment outcomes and verifying the efficacy of topiramate and naltrexone to decrease the use of cigarettes among alcoholic smokers. Methods: The investigation was a double-blind, placebo-controlled, 12-week study carried out at the University of Sao Paulo, Brazil. The sample comprised 155 male alcohol-dependent outpatients (52 nonsmokers and 103 smokers). 18-60 years of age, with an International Classification of Diseases (ICD-10) diagnosis of alcohol dependence. After a 1-week detoxification period, the patients randomly received placebo, naltrexone (50 mg/day) or topiramate (up to 300 mg/day). Only the alcoholic smokers who adhered to the treatment were evaluated with reference to the smoking reduction. Results: Cox regression analysis revealed that the smoking status among alcoholics increased the odds of relapse into drinking by 65%, independently of the medications prescribed, using the intention-to-treat method. Topiramate showed effectiveness to reduce the number of cigarettes smoked when compared to placebo among adherent patients (mean difference =7.91, p < 0.01). There were no significant differences between the naltrexone group and the placebo group. Conclusions: The results of this study confirm that the treatment is more challenging for smoking alcoholics than for non-smoking ones and support the efficacy of topiramate in the smoking reduction among male alcoholic smokers who adhered to the treatment. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

CISA (Centro de Informacoes sobre Saude a Alcool-Center for Information on Health and Alcohol)

pharmacy sector at the Psychiatric Institute of the Clinical Hospital of the University of Sao Paulo (USP), Brazil

Identificador

DRUG AND ALCOHOL DEPENDENCE, v.105, n.1/Fev, p.33-41, 2009

0376-8716

http://producao.usp.br/handle/BDPI/22543

10.1016/j.drugalcdep.2009.05.025

http://dx.doi.org/10.1016/j.drugalcdep.2009.05.025

Idioma(s)

eng

Publicador

ELSEVIER IRELAND LTD

Relação

Drug and Alcohol Dependence

Direitos

restrictedAccess

Copyright ELSEVIER IRELAND LTD

Palavras-Chave #Tobacco #Alcoholism #Pharmacotherapy #Treatment #RANDOMIZED CONTROLLED-TRIAL #NICOTINE REPLACEMENT THERAPY #SMOKING-CESSATION #CIGARETTE-SMOKING #DRINKING BEHAVIOR #ORAL TOPIRAMATE #ABUSE TREATMENT #QUIT SMOKING #SMOKERS #INDIVIDUALS #Substance Abuse #Psychiatry
Tipo

article

original article

publishedVersion